Literature DB >> 15754413

Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma.

Ke-Jun Nan1, Hui Guo, Zhi-Ping Ruan, Zhao Jing, Shaan-Xi Liu.   

Abstract

AIM: To investigate the expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma (HCC).
METHODS: Expression of p57(kip2), PCNA and p53 in tumor tissues from 32 patients with HCC and 10 liver tissues of normal persons was detected with Elivision immunohistochemical technique.
RESULTS: The p57(kip2) protein positive-expression rate in HCC was 56.25%, lower than that in normal tissues (100%, P<0.05). The reduced expression of p57(kip2) protein correlated significantly with moderate or low differentiation of tumor cells (P = 0.007 <0.05), high clinical stage (P = 0.041 <0.05) and poor prognosis (P = 0.036 <0.05), but did not correlate significantly with metastasis, tumor size, level of AFP and age (P>0.05). The PCNA positive-expression rate was 56.25%, which was correlated significantly with the expression of p57(kip2) (P = 0.025<0.05). The p53 positive-expression rate was 46.88%, which was not correlated significantly with the expression of p57(kip2) (P>0.05).
CONCLUSION: There is a marked loss or absence of p57(kip2) expression and high expression of PCNA in HCC, which are involved in carcinogenesis and development of HCC. The p57(kip2) and p53 may induce apoptosis via different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754413      PMCID: PMC4250722          DOI: 10.3748/wjg.v11.i8.1237

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development.

Authors:  Y Yan; J Frisén; M H Lee; J Massagué; M Barbacid
Journal:  Genes Dev       Date:  1997-04-15       Impact factor: 11.361

2.  Immunohistochemical assessment of proliferating cell nuclear antigen in primary hepatocellular carcinoma and dysplastic nodules.

Authors:  A Saftoiu; T Ciurea; Claudia Georgescu; Monica Banita; Violeta Comanescu; I Rogoveanu; F Gorunescu; I Georgescu
Journal:  J Cell Mol Med       Date:  2003 Oct-Dec       Impact factor: 5.310

3.  Expression of second class of KIP protein p57KIP2 in human colorectal carcinoma.

Authors:  S Noura; H Yamamoto; M Sekimoto; I Takemasa; Y Miyake; M Ikenaga; N Matsuura; M Monden
Journal:  Int J Oncol       Date:  2001-07       Impact factor: 5.650

4.  Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

Authors:  E Rosenberg; R I Demopoulos; A Zeleniuch-Jacquotte; H Yee; J Sorich; J L Speyer; E W Newcomb
Journal:  Hum Pathol       Date:  2001-08       Impact factor: 3.466

5.  P57 (KIP2) polymorphisms and breast cancer risk.

Authors:  Y Li; R C Millikan; B Newman; K Conway; C K Tse; E T Liu
Journal:  Hum Genet       Date:  1999-01       Impact factor: 4.132

6.  Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma.

Authors:  Yasuhiro Ito; Tsutomu Takeda; Yo Sasaki; Masato Sakon; Terumasa Yamada; Shingo Ishiguro; Shingi Imaoka; Masahiko Tsujimoto; Morito Monden; Nariaki Matsuura
Journal:  Liver       Date:  2002-04

Review 7.  Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells.

Authors:  Paul Yaswen; Martha R Stampfer
Journal:  Int J Biochem Cell Biol       Date:  2002-11       Impact factor: 5.085

8.  [Determination of expression of eight p53-related genes in hepatocellular carcinoma with tissue microarrays].

Authors:  Ming-Hua Zhu; Can-Rong Ni; Zhi Zhu; Fang-Mei Li; Shun-Min Zhang
Journal:  Ai Zheng       Date:  2003-07

9.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

10.  p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus.

Authors:  Tomotaka Yokoo; Hideo Toyoshima; Mitsuhiro Miura; Yuhui Wang; Kaoruko Tada Iida; Hiroaki Suzuki; Hirohito Sone; Hitoshi Shimano; Takanari Gotoda; Shigeki Nishimori; Keiji Tanaka; Nobuhiro Yamada
Journal:  J Biol Chem       Date:  2003-10-06       Impact factor: 5.157

View more
  6 in total

1.  Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a).

Authors:  Pinar Atasoy; Erdal Yilmaz; Onder Bozdogan; Sebnem Ayva; Ertan Batislam
Journal:  Int Urol Nephrol       Date:  2008-06-03       Impact factor: 2.370

2.  Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.

Authors:  Hai-Jian Zhang; Deng-Fu Yao; Min Yao; Hua Huang; Wei Wu; Mei-Juan Yan; Xiao-Di Yan; Jie Chen
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

Review 3.  Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.

Authors:  Massimiliano Berretta; Carla Cavaliere; Lara Alessandrini; Brigida Stanzione; Gaetano Facchini; Luca Balestreri; Tiziana Perin; Vincenzo Canzonieri
Journal:  Oncotarget       Date:  2017-02-21

4.  Relevance of immunohistochemical expression of p57kip2 in epithelial ovarian carcinoma- A systematic literature review.

Authors:  Thumuluru Kavitha Madhuri; Anil Tailor; Ben Haagsma; Helen Coley; Simon Butler-Manuel
Journal:  J Ovarian Res       Date:  2012-12-21       Impact factor: 4.234

5.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

6.  High Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.

Authors:  Chengcheng Yang; Haocheng Nan; Jiequn Ma; Lili Jiang; Qianqian Guo; Lili Han; Yamin Zhang; Kejun Nan; Hui Guo
Journal:  Breast Cancer (Auckl)       Date:  2015-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.